

CC The present sequence represents a gene encoding a human secreted protein

CC (see descriptor line for gene number and clone identification).

XX

SQ Sequence 1687 BP; 502 A; 363 C; 508 G; 302 T; 12 other;

Query Match 76.2%; Score 288; DB 20; Length 1687;
Best Local Similarity 100.0%; Pred. No. 1.1e-136;
Matches 288; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;

Qy 91 CGGGGTCACCAGTTATTAGAGGAAGTAACACAAGGGGATATGAGTGCAGCAGACACATTT
150

Db 1 CGGGGTCACCAGTTATTAGAGGAAGTAACACAAGGGGATATGAGTGCAGCAGACACATTT
60

Qy 151 CTGTCCGATCTGCCAAGGGATGATATCTATGTGTCAGATGTTGAGGACGACGGTGATGAC
210

Db 61 CTGTCCGATCTGCCAAGGGATGATATCTATGTGTCAGATGTTGAGGACGACGGTGATGAC
120

Qy 211 ACATCTCTGGATAGTGACCTGGATCCAGAGGAGCTGGCAGGAGTCAGGGGACATCAGGGT
270

Db 121 ACATCTCTGGATAGTGACCTGGATCCAGAGGAGCTGGCAGGAGTCAGGGGACATCAGGGT
180

Qy 271 CTAAGGGACCAAAAGCGTATGCGACTTACTGAAGTGCAAGATGATAAAGAGGAGGAGGAG
330

Db 181 CTAAGGGACCAAAAGCGTATGCGACTTACTGAAGTGCAAGATGATAAAGAGGAGGAGGAG
240

Qy 331 GAGGAGAATCCACTGCTGGTACCACTGGAGGAAAAGGCAGTACTGCAG 378
|||||

Db 241 GAGGAGAATCCACTGCTGGTACCACTGGAGGAAAAGGCAGTACTGCAG 288

RESULT 5

AAV84559

ID AAV84559 standard; DNA; 1687 BP.

XX

AC AAV84559;

XX

DT 01-MAR-1999 (first entry)

XX

DE Human secreted protein gene 149 clone HLMMU76.

XX

KW Human; secreted protein; fusion protein; gene therapy; protein therapy;

KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;

KW developmental abnormality; foetal deficiency; blood; allergy; renal; ds;

KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;

KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;

KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;

KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;

KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.

XX

OS Homo sapiens.

XX

PN WO9854963-A2.

XX

PD 10-DEC-1998.

XX

PF 04-JUN-1998; 98WO-US11422.

XX

PR 18-DEC-1997; 97US-0070923.

PR 06-JUN-1997; 97US-0048877.

PR 06-JUN-1997; 97US-0048881.

PR 06-JUN-1997; 97US-0048884.

PR 06-JUN-1997; 97US-0048893.

PR 06-JUN-1997; 97US-0048896.

PR 06-JUN-1997; 97US-0048899.

PR 06-JUN-1997; 97US-0048915.

PR 06-JUN-1997; 97US-0048949.

PR 06-JUN-1997; 97US-0048964.

PR 06-JUN-1997; 97US-0048972.

PR 06-JUN-1997; 97US-0049020.

PR 06-JUN-1997; 97US-0049375.

PR 05-SEP-1997; 97US-0057628.

PR 05-SEP-1997; 97US-0057635.

PR 05-SEP-1997; 97US-0057644.

PR 05-SEP-1997; 97US-0057647.

PR 05-SEP-1997; 97US-0057650.

PR 05-SEP-1997; 97US-0057661.

PR 05-SEP-1997; 97US-0057667.

PR 05-SEP-1997; 97US-0057761.

PR 05-SEP-1997; 97US-0057764.

PR 05-SEP-1997; 97US-0057770.
PR 05-SEP-1997; 97US-0057775.
PR 05-SEP-1997; 97US-0057778.
PR 06-JUN-1997; 97US-0048875.
PR 06-JUN-1997; 97US-0048878.
PR 06-JUN-1997; 97US-0048882.
PR 06-JUN-1997; 97US-0048885.
PR 06-JUN-1997; 97US-0048894.
PR 06-JUN-1997; 97US-0048897.
PR 06-JUN-1997; 97US-0048900.
PR 06-JUN-1997; 97US-0048916.
PR 06-JUN-1997; 97US-0048962.
PR 06-JUN-1997; 97US-0048970.
PR 06-JUN-1997; 97US-0048974.
PR 06-JUN-1997; 97US-0049373.
PR 05-SEP-1997; 97US-0057584.
PR 05-SEP-1997; 97US-0057629.
PR 05-SEP-1997; 97US-0057642.
PR 05-SEP-1997; 97US-0057645.
PR 05-SEP-1997; 97US-0057648.
PR 05-SEP-1997; 97US-0057651.
PR 05-SEP-1997; 97US-0057662.
PR 05-SEP-1997; 97US-0057668.
PR 05-SEP-1997; 97US-0057762.
PR 05-SEP-1997; 97US-0057765.
PR 05-SEP-1997; 97US-0057771.
PR 05-SEP-1997; 97US-0057776.
PR 06-JUN-1997; 97US-0048876.
PR 06-JUN-1997; 97US-0048880.
PR 06-JUN-1997; 97US-0048883.
PR 06-JUN-1997; 97US-0048892.
PR 06-JUN-1997; 97US-0048895.
PR 06-JUN-1997; 97US-0048898.
PR 06-JUN-1997; 97US-0048901.
PR 06-JUN-1997; 97US-0048917.
PR 06-JUN-1997; 97US-0048963.
PR 06-JUN-1997; 97US-0048971.
PR 06-JUN-1997; 97US-0049019.
PR 06-JUN-1997; 97US-0049374.
PR 05-SEP-1997; 97US-0057627.
PR 05-SEP-1997; 97US-0057634.
PR 05-SEP-1997; 97US-0057643.
PR 05-SEP-1997; 97US-0057646.
PR 05-SEP-1997; 97US-0057649.
PR 05-SEP-1997; 97US-0057654.
PR 05-SEP-1997; 97US-0057666.
PR 05-SEP-1997; 97US-0057760.
PR 05-SEP-1997; 97US-0057763.
PR 05-SEP-1997; 97US-0057769.
PR 05-SEP-1997; 97US-0057774.
PR 05-SEP-1997; 97US-0057777.

XX

PA (HUMA-) HUMAN GENOME SCI INC.

XX

PI Brewer LA, Carter KC, Dillon PJ, Ebner R, Endress GA;
PI Fan P, Feng P, Ferrie AM, Fischer CL, Florence C;
PI Florence K, Greene JM, Hu J, Kyaw H, Lafleur DW;

PI Li Y, Moore PA, Ni J, Olsen HS, Rosen CA, Ruben SM;
 PI Shi Y, Soppet DR, Wei Y, Young P, Yu G, Zeng Z;
 XX
 DR WPI; 1999-059865/05.
 DR P-PSDB; AAW88682, AAW89010, AAW89011, AAW89012.
 XX
 PT New isolated human genes and the secreted polypeptides they encode
 -
 PT useful for diagnosis and treatment of e.g. cancers, neurological
 PT disorders, immune diseases, inflammation or blood disorders
 XX
 PS Claim 4; Page 410-411; 772pp; English.
 XX
 CC The invention relates to nucleic acid sequences (AAV84411 to
 AAV84633)
 CC encoding human secreted proteins (AAW88534 to AAW88756). The
 secreted
 CC protein gene sequences are deposited with the ATCC under deposit
 numbers
 CC ATCC 97979, 97974, 97975, 97976, 97977, 209007, 209008, 209009,
 209010,
 CC 209011, 209080, 209081, 209082, 209083, 209084, 209085, 209511.
 Host
 CC cells comprising recombinant vectors containing the nucleic acid
 CC sequences are used for the recombinant production of the secreted
 CC proteins. The polynucleotide and amino acid sequences are useful
 for are
 CC useful for preventing, treating or ameliorating medical conditions
 e.g.
 CC by protein or gene therapy. Pathological conditions can be also
 CC diagnosed by determining the amount of the new polypeptides in a
 sample
 CC or by determining the presence of mutations in the new
 polynucleotides.
 CC Specific uses are described for each of the polynucleotides, based
 on
 CC which tissues they are most highly expressed in, and include
 developing
 CC products for the diagnosis or treatment of cancer,
 neurodegenerative
 CC disorders, developmental abnormalities and foetal deficiencies,
 blood
 CC disorders, tumours, leukemias, diseases of the immune system,
 autoimmune
 CC diseases, hepatic and renal disease, lymphomas, inflammation,
 allergies,
 CC ischemic shock, Alzheimer's and cognitive disorders,
 schizophrenia,
 CC restenosis, prostate diseases, obesity, disorders involving
 osteoclasts
 CC such as osteoporosis, arthritis or malignancies, diseases of
 testes,
 CC lung or thymus, digestive/endocrine disorders, infections and
 AIDS. The
 CC polypeptides are also useful for identifying their binding
 partners.